Skip to content

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525844-14-00
Enrollment
36
Registered
2026-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-Stage Kidney Disease (ESKD)

Interventions

None listed

Sponsors

Regeneron Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 4, 2026